

Table of Contents

Chapter 1: Introduction and Review of Literature	1
1. Female Reproductive System.....	1
1.1 Ovary.....	1
1.2 Folliculogenesis.....	2
1.3 Follicular steroidogenesis.....	5
1.4 Two cell two gonadotropin theory	7
1.5 Follicular Atresia.....	8
1.5.1 Apoptosis.....	8
1.5.2 Mechanisms of apoptosis.....	9
1.5.3 Regulation of apoptosis in the ovary	10
1.6 Synchrony amongst Ovary, Brain and Pituitary.....	11
1.7 Factors involved in follicular growth	12
1.7.1 Insulin and Insulin receptor (INSR):	12
1.7.2 Insulin like growth factor system	13
1.8 Insulin and IGF Signaling mechanism	14
1.9 Signaling in Granulosa cell	16
1.10 Granulosa cell metabolism	17
1.11 Infertility.....	18
1.11.1 Epidemiology.....	19
1.11.2 Etiological factors for infertility	19
1.12 Insulin resistance (IR)	21
1.13 Diagnosis of insulin resistance (IR)	22
1.14 Cellular and molecular mechanisms of insulin resistance (IR).....	23
1.15 Insulin resistance (IR) at hypothalamus and pituitary.....	24
1.16 Insulin resistance (IR) at ovary	25
1.17 Insulin resistance and conception.....	26
1.18 Insulin Resistance and Cadmium	27
1.19 Endocrine disruptors	27
1.20 Cadmium	28
1.20a Cadmium and reproductive dysfunctions	28
1.20b Toxic effects of Cd in the hypothalamus.....	28
1.20c Toxic effects of Cd in the pituitary gland	29
1.20d Toxic effects of Cd in the ovary	29
1.21 Animal models	31
1.22 Human models.....	32
1.23 Interventions for infertility	33
1.23.1 Life style modifications	33
1.23.2 Pharmacological interventions	33
1.23.3 Insulin-sensitizing drugs (ISDs)	34
1.23.4 Herbal medicine in treatment of Insulin resistance	36
1.24 References:	39

Chapter 2: Aims and Objectives.....	50
2.1 Aim and Rationale for the study	50
2.2 Objectives.....	52
2.2.1: To study the effect of cadmium on cell death and expression of steroidogenic and major candidate genes in insulin resistant rat ovarian cells.....	52
2.2.2: To study the effect of sub-clinical dose of cadmium on steroidogenesis in insulin resistant human granulosa cells.	52
2.2.3: To elucidate mechanism underlying insulin and steroidogenic signaling in insulin resistant and non-insulin resistant human granulosa cells.....	52
2.2.4: To identify insulin sensitizer bioactive compound to ameliorate insulin resistance and steroidogenic dysfunction in human granulosa cells.	52
Chapter 3: Materials and methods.....	53
3.1 Hormones and reagents	53
3.2 Antibodies	53
3.3 Animals and Experimental Design.....	53
3.4 Selection of IR animals and confirmation of IR	54
3.5 Estrous cyclicity	54
3.6 Histological analysis	54
3.7 Granulosa cell isolation from rat.....	55
3.8 Human follicular fluid collection	55
3.9 Human granulosa-luteal cell isolation and culture	56
3.10 Immunocytochemistry.....	56
3.11 Atomic absorption spectroscopy (AAS) for Cd analysis	57
3.12 Measurement of Cd toxicity.....	57
3.13 In vitro culture of hLGC with Cd.....	57
3.14 Human granulosa cell culturing with bioactives	58
3.15 Total RNA Extraction, RT-PCR and qRT-PCR.....	58
3.16 Western blot analysis	59
3.17 Estimation of hydroxysteroid dehydrogenase activity.....	60
3.18 Annexin V binding assay	60
3.19 Follicular fluid and hLGC culture hormone analysis.....	60
3.20 Statistical Analysis	61
3.21 References:.....	61
Chapter 4: To study the effect of cadmium on cell death and expression of steroidogenic and major candidate genes in insulin resistant rat ovarian cells.	62
4.1 Introduction	62
4.2 Experimental Design	65
4.3 Results	66
4.3.1 Induction of IR is solely because of dexamethasone.....	66
4.3.2 Effect of Cd and IR on Estrous Cyclicity	67
4.3.3 Histological Analysis revealed alterations in ovary	67
4.3.4 Granulosa cell viability.....	68
4.3.5 Effect of Cd and IR on cell death parameters in granulosa cell	69
4.3.6 Effect of Cd and IR on serum estradiol and progesterone concentrations	70

4.3.7 Expression of genes and proteins involved in steroidogenesis in rat granulosa cells.....	71
4.3.8 Effect of Cd and IR on steroidogenic enzyme activity.....	72
4.3.9 Expression of genes for gonadotropin receptors in rat granulosa cells.....	73
4.3.10 Expression of genes involved in regulation of steroidogenesis.....	73
4.4 Discussion.....	74
4.5 References.....	81
Chapter 5: To study the effect of subclinical dose of cadmium on steroidogenesis in insulin resistant human luteinized granulosa cells.....	84
5.1 Introduction.....	84
5.2 Experimental Design.....	87
5.3 Results.....	88
5.3.1 Characterization of cells isolated from follicular fluid.....	88
5.3.2 Insulin Resistance confirmation in PCOS-hLGC's.....	88
5.3.3 Cd concentration in follicular fluid.....	89
5.3.4 Effect of Cd exposure on viability of control and PCOS-IR hLGC's.....	89
5.3.5 Effect of Cd and IR on cell death parameters in hLGC's.....	90
5.3.6 Effect of Cd and IR on steroid concentrations in hGLC's.....	91
5.3.7 Effect of Cd and IR on expression of steroidogenic genes- proteins in LGC's.....	92
5.3.8 Effect of Cd and IR on hydroxy steroid dehydrogenase activity in hLGC's.....	93
5.3.9. Effect of IR and Cd on expression of gonadotropin receptors genes in hLGC's.....	93
5.4 Discussion.....	94
5.5 References:.....	98
Chapter 6: To elucidate mechanism underlying insulin and steroidogenic signalling in insulin resistant and non-insulin resistant human luteinized granulosa cells.....	102
6.1 Introduction.....	102
6.2 Experimental Design.....	104
6.3 Results.....	105
6.3.1 Characterization of IR in granulosa cell and assessment of viability.....	105
6.3.2 Insulin signalling is altered in PCOS-IR and PCOS-NIR.....	105
6.3.3 Fat metabolism genes are altered in PCOS-IR.....	106
6.3.4. Expression of steroidogenic genes and proteins is altered in PCOS-IR and NIR.....	107
6.3.5 Steroid hormones are altered in follicular fluid from PCOS-IR and PCOS-NIR.....	108
6.3.6 mRNA expression of FSH-R and LH-R are altered in PCOS-IR and NIR.....	108
6.3.7 Insulin like growth system (IGF) is altered in PCOS-IR and NIR.....	109
6.4 Discussion.....	109
6.5 References.....	114
Chapte 7: To identify insulin sensitizer bioactive compound to ameliorate insulin resistance and steroidogenic dysfunction in human luteinized granulosa cells from PCOS.....	118
7.1 Introduction.....	118
7.2 Experimental Design.....	122

7.3 Results	123
7.3.1 Bio active molecules increase hLGC viability from PCOS-IR with no change in PCOS-NIR.	123
7.3.2 Divergent effects of swertiamarin and curcumin on insulin signalling proteins in hLGC's from PCOS-IR and PCOS-NIR.	123
7.3.3 Swertiamarin and curcumin could reverse variations in the Lipogenic genes	125
7.3.4 Swertiamarin and curcumin reversed the decrease in steroidogenesis in hLGC's from PCOS-IR	125
7.3.5 Swertiamarin and curcumin had no effect on steroidogenesis in hLGC's from PCOS-NIR	126
7.3.6 Swertiamarin and curcumin reversed the enzyme activity only in hGLC's from PCOS-IR	127
7.3.7 Swertiamarin and curcumin reverted the steroid hormone levels only in hGLC's from PCOS-IR	127
7.3.8 Swertiamarin and curcumin reversed the gonadotropin hormones only in hGLC's from PCOS-IR	128
7.3.9 Swertiamarin and curcumin are capable of reversing variations in the IGF system	129
7.4 Discussion	129
7.5 References	134
Chapter 8: Summary and Conclusion.....	137
8.1 Summary	137
8.2 Conclusion.....	140
List of Figures.....	vi
List of Tables	ix